$IGC News

Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $6

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

IGC Pharma Says CEO Ram Mukunda And Principal Financial Officer Claudia Grimaldi Purchase Aggregate Of 4,274,853 Shares Directly From Company At $0.27/Shr

IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

IGC Pharma Launches AI-Powered Data Harmonization Platform To Accelerate Alzheimer’s Research And Drug Discovery

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.5

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

IGC Pharma Announces Addition Of Icahn School Of Medicine At Mount Sinai In New York As Clinical Site In Phase 2 CALMA Trial Evaluating IGC-AD1 For Agitation Associated With Alzheimer's Disease

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

IGC Pharma Adds Kerwin Medical Center In Dallas, Texas As Clinical Site In Phase 2 CALMA Trial Evaluating IGC-AD1 For Agitation In Alzheimer's Disease